Hematology NewsTreatment simulation could help personalize myeloma therapyJuly 31, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesCHMP recommends expanded approval for daratumumabJuly 31, 2018Multiple MyelomaPharmacy
Hematology TimesCHMP backs 2 biosimilar pegfilgrastim productsJuly 31, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy
Hematology TimesGlobal burden of hematologic malignanciesJuly 29, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
Hematology NewsMyeloma frailty index predicts survival based on biological ageJuly 25, 2018Multiple MyelomaLeukemia, Myelodysplasia, TransplantationPatient & Survivor Care
Hematology TimesFDA approves biosimilar filgrastimJuly 22, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaTransplantationAMLALL
Hematology TimesDiabetics have higher risk of hematologic, other cancersJuly 20, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
Hematology NewsAdding elotuzumab improves myeloma PFS over pom/dex aloneJuly 18, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
CAR T Therapy: From Bench to Bedside and BackJuly 15, 2018AnemiaLeukemia, Myelodysplasia, TransplantationALLAMLCellular TherapyLymphoma & Plasma Cell DisordersMultiple Myeloma
Hematology NewsPromising phase 3 results for ixazomib in multiple myelomaJuly 13, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
